A Study to Investigate Use of Off-the-shelf Natural Killer (NK) Cells (SAR445419) in Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
← catalyst calendarNCT05726682 · readout in 177 d
Sponsored by Sanofi (industry) · SNY — their whole pipeline →.
Phase
Phase 2
Status
Withdrawn
Study type
Interventional
Design
Na · None · Treatment
Enrollment
0actual
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Why the sponsor stopped it
Sponsor decision to cancel trial, not related to safety concern.
As filed on the registry record, in the sponsor's own words.
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-10-08 | estimated | When the study began enrolling |
| Primary completion | 2027-02-12 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-10-11 | estimated | The whole study's end, after follow-up |
| First posted | 2023-02-14 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2024-03-05 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Allogenic Stem Cell Transplantation
Intervention
- Drug: SAR445419
Primary outcomes
what the primary-completion date above is the date OFRate of relapse free survival (RFS) post allogeneic hematopoietic stem cell transplantation (HSCT)
measured 12 months post HSCT
Frequency of cytomegalovirus (CMV) reactivation/infection in CMV seronegative participants who receive a CMV seronegative HSCT graft
measured From baseline up to 2 years
Frequency of life-threatening (grade 4) infusion related reactions (IRR) or cytokine release syndrome (CRS) that does not resolve to grade 1 within 72 hours despite therapy
measured From baseline up to 2 years
Frequency of life threatening (grade 4) tumor lysis syndrome (TLS)
measured From baseline up to 2 years
Frequency of life-threatening (grade 4) immune cell-associated neurotoxicity syndrome (ICANS) that does not resolve to grade 1 within 72 hours despite therapy
measured From baseline up to 2 years
Frequency of grade 3-4 acute graft versus host disease (aGVHD)
measured From baseline up to 2 years
Frequency of non-relapse mortality (NRM)
measured 100 days post HSCT
Frequency of graft failure
measured 100 days post HSCT
Frequency of overall mortality
measured 100 days post HSCT
Permalink · SNY's whole pipeline · Catalyst calendar · Every registered study · What changed